Zivo Bioscience Insider Bought Shares Worth $1,514,250, According to a Recent SEC Filing
Express News | Zivo Bioscience Reports Progress With Coccidiosis Treatment Licensing Opportunities
ZIVO Bioscience Reports Progress With Coccidiosis Treatment Licensing Opportunities
Express News | Zivo Bioscience: Study Showed Delay in Transmission of Lpai When Healthy Birds Were Exposed to Infected Birds
ZIVO Bioscience Reports Preliminary Efficacy of Its Proprietary Active Ingredients in the Battle Against Avian Influenza
Express News | Zivo Bioscience Reports Preliminary Efficacy of Its Proprietary Active Ingredients in the Battle Against Avian Influenza
Maxim Group Maintains Zivo Bioscience(ZIVO.US) With Hold Rating
Maxim Group Keeps Their Hold Rating on Zivo Bioscience (ZIVO)
10-Q: Q3 2024 Earnings Report
Director and 10% Owner Christopher Maggiore Acquires 31,336 Shares of Zivo Bioscience Inc (ZIVO)
Express News | Zivo Reports Favorable Results From 42-Day Confirmatory Study of Its Coccidiosis Treatment in Broiler Chickens
10-Q: Q2 2024 Earnings Report
Zivo Bioscience Strengthens Board With New Director Appointment
Major Global Animal Health Company Launches 42-Day Confirmatory Study With ZIVO Bioscience's Coccidiosis Treatment in Broiler Chickens
Express News | Maxim Group has downgraded Zivo Bioscience (ZIVO.US) from a buy rating to a hold rating.
Maxim Group Downgrades Zivo Bioscience to Hold
Zivo Bioscience Analyst Ratings
Maxim Group Downgrades Zivo Bioscience(ZIVO.US) to Hold Rating
Maxim Group analyst Anthony Vendetti downgrades $Zivo Bioscience(ZIVO.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 30.3% and a total average return of -8.6% over
10-Q: Q1 2024 Earnings Report
Zivo Bioscience (ZIVO) Gets a Buy From Maxim Group